Ensysce Biosciences Inc (ENSC)

[TheFinalCD]

$ENSC Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
https://www.accesswire.com/viewarticle.aspx?id=829496

[Awl416]

Damn

[TimeFades]

In again

[TimeFades]

What’s next big man

[TimeFades]

Flipperooni

[TrendTrade2016]

2.09 FIRST TARGET WORKED...ALL OUT

[TrendTrade2016]

NEW TARGET IN/...2.29 WATCH AND LEARN

[TrendTrade2016]

BOOOM BOOOM...WHOS YA DADDY...2.09 HERE WE GO

[TrendTrade2016]

WATCH HOW THE MASTER NAVIGATES THIS TRADE

[TrendTrade2016]

ENSC...TNIN TO 2.00

[TrendTrade2016]

ENSC...BREAL 1.88...THEN 2.09

[TimeFades]

Overnight beaut

[TimeFades]

In

[TimeFades]

I’m tight stop

[TrendTrade2016]

TOO THICK AT 1.70

[TrendTrade2016]

ENSC....MONSTER BIO

[TrendTrade2016]

ENSC...HERE WE GO

[TrendTrade2016]

ENSC..LOOKS LIKE A MULTI DAY RUNNER

[TrendTrade2016]

ENSC...BIO RUNNER

[Invest-in-America]

ENSC: Why is price up??? (Because it's UP, right??? Don't ya just LOVE website articles like THAT???)

[Awl416]

Form RW - Registration Withdrawal Request

[BooDog]

Thinking their convertibles will hold this back for a bit. Getting ready to give away even more...

https://ih.advfn.com/stock-market/NASDAQ/ensysce-biosciences-ENSC/stock-news/92404486/form-pre-14a-other-preliminary-proxy-statements


Low of .81 yesterday. Dodged the drop on this but still keeping it on my list.

[Monksdream]

ENSC new 52 week low

[BooDog]

H&S, looks like this'll be under the $. Keeping it on radar though.

[Monksdream]

ENSC new 52 week low

[Golden Cross]

Next $10 Bio runner by EOY

[BooDog]

1.80 high, so far. Like to see this fill the gap in the 1.40's. Liking the swings though for sure.

[BooDog]

Some decent swing action this morning.

[Backstabbed]

Hmmm… since you are here, I believe that something may come out of it

[BooDog]

High 1.53. $ENSC

[BooDog]

Wasn't even on my list. Nice Monk!

[Monksdream]

Bought TPST last night at 48 cents
ENSC is nothing

[BooDog]

This needs the volume to really do anything. Getting some pincher indicators, and if any volume does start coming in the float is smal enough to let it rip.

Roll of the dice right now imo.

[Monksdream]

ENSC new 52 week low

[Monksdream]

ENSC under $2

[twitchy]

What a blood bath! This POS is by far the worst stock I've ever bought… and I play the OTC! Go ENSC - just need it to hit $317 to break even.

[Monksdream]

ENSC new 52 week low

[trendzone]

Sooner later if some big news hits the wires, there is going to be a bloodbath of shorts lying in a ditch on the side of the road, covered in so much of each other's blood, that it will be seen from space as a big red dot.

[trendzone]

There is some very corrupted hedge funds involved with the manipulation trading activity in this stock, like the example in the warrants every time there is a big buyer of them like today at $0.015 some little moron sells like one warrant back on the bid, like a little spiteful 12 year old kid, it's gotten to the point that a group of investors have contacted the SEC to request an open investigation for any noticeable stock manipulation, and were told they will monitor it in the future for any that violations.

[BooDog]

rediculous float. https://finviz.com/quote.ashx?t=ENSC&p=d

Anything good happens here and what's left of the shorts will be toast. Offering was in the 3.80's.

Presentation coming up in Las Vegas.


Roll the dice baby!!

[Invest-in-America]

ENSC: Indeed, Sir --- and, up a little in the A.H. right now; as @VINE goes down the proverbial toilet in the A.H. (NOT to disparage those who scored huge today over on THAT one.)

[trendzone]

Shorters will have more pain ahead, better start start loading the warrants as an hedge for when it blast through $3.00 and keeps gasping higher.

[Invest-in-America]

ENSC: O.K., nice price prediction to $9.00.

[subslover]

nsysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
~ Represents Major Milestone Towards Launch of PF614-MPAR ~

~ PF614-MPAR on Track to be the First Drug to Protect Against Overdose ~

SAN DIEGO, CA / ACCESSWIRE / May 9, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR successfully reduced opioid delivery when three or more doses are consumed simultaneously.

We believe PF614-MPAR is the first drug which can limit opioid exposure when too many pills are swallowed, protecting against overdose. In our PF614-MPAR-101 study, the data showed that a 25 mg dose of PF614-MPAR, delivered oxycodone as designed for what may be a prescribed dose of one to two capsules. Importantly, when administering three or more capsules simultaneously, the amount of opioid released and absorbed into the circulation diminished as compared to the unprotected PF614, thereby substantially reducing the risk of overdose.

Opioids are used widely for the treatment of severe pain, for example, in patients fighting cancer and for post-operative pain. Opioids are highly effective but carry a significant risk of abuse, addiction and overdose. Overdoses with opioids continue to be a major issue which may occur due to inadvertent over-use, or purposefully when family members find drugs to experiment with in the medicine cabinet.

According to Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, "This first-in-human demonstration of MPAR's unique ability to reduce the adverse consequences of excessive opioid consumption is a major step towards Ensysce's goal of making safer prescription drugs. If approved by the FDA, PF614-MPAR could represent a true game-changer for the treatment of severe pain, and could validate our MPAR™ technology for application to a range of other medications."

"This successful outcome brings us closer to the launch of the first opioid with overdose protection," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. "PF614-MPAR is potentially a first-in-class agent designed to treat severe pain while not only reducing the ability to abuse for recreational purposes but also to provide protection from overdose. The results showed that our patented technology MPAR™, which ‘switches off' the active drug release, can limit delivery when excess was consumed. Our next step is to clearly define the drug product for all planned dose strengths to optimize effects across our planned dose range. The PF614-MPAR-101 study is particularly important as a proof-of-concept for the base MPAR™ technology which we believe could be used to control delivery of many other drug classes where there may be a narrow therapeutic range. We are excited to explore this further with other therapies as it may help to save many lives in the future."

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-resistant treatment option for pain that minimizes the risk of both opioid drug abuse and accidental or intentional overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter

[MiamiGent]

ENSC Ensysce Biosciences

Have a sizeable position at .65

My thesis is a Director recently bot a boatload on the open mkt in the higher .40s, lol

News this morning did nothing good. Closed tonight at $0.5017 -$0.0478 (-8.699%)

https://ir.ensysce.com/news/press-releases/detail/104/ensysce-biosciences-announces-completion-of-enrollment-for

[Shift-4]

This is by far the most manipulated ticker I've ever encountered. Don't get shook; this isn't sustainable manipulation.

The PR today wasn't the big news- it's the abuse potential results from study 2 that are the big tuna of the moment, expected before end of month.

-$

[MiamiGent]

ENSC Took a stab at .68
Inside buying on open market and..
Trial Report or something coming soon... :)

Some clinical stage bios warrant consideration, when they look legit. I checked. The low PPS is part and parcel of this category

https://stockcharts.com/h-sc/ui?s=ENSC

[StockLogistics]

“Ensysce Biosciences

The Trade: Ensysce Biosciences, Inc. (NASDAQ: ENSC) Director Bob G Gower bought a total of 90,287 shares at an average price of $0.49. To acquire these shares, it cost around $44.09 thousand.
What's Happening: Ensysce Biosciences announced critical step in human abuse potential study of PF614 with database lock.
What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.“

[2times2]

appreciated! Minimum just 1$ pps. Revisited in June

[Shift-4]

https://seekingalpha.com/news/3937233-nasdaq-nods-ensysce-biosciences-for-continued-listing?utm_source=otcmarkets&utm_medium=referral

-$